ATH 1020
Alternative Names: ATH-1020Latest Information Update: 28 Apr 2025
At a glance
- Originator Athira Pharma
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
- No development reported Neurological disorders; Psychiatric disorders
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Neurological-disorders(In the elderly, In volunteers, In adults) in USA (PO, Capsule)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Psychiatric-disorders(In the elderly, In volunteers, In adults) in USA (PO, Capsule)
- 05 Jan 2023 Adverse events data from a phase I pharmacokinetics trial released by Athira Pharma